标题
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
作者
关键词
-
出版物
OncoImmunology
Volume 4, Issue 3, Pages e989771
出版商
Informa UK Limited
发表日期
2015-04-03
DOI
10.4161/2162402x.2014.989771
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses
- (2014) Andrew Zloza et al. Journal for ImmunoTherapy of Cancer
- HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection
- (2013) Wei Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
- (2013) T Yamazaki et al. CELL DEATH AND DIFFERENTIATION
- Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus
- (2013) A. Kanerva et al. CLINICAL CANCER RESEARCH
- HMGB1 in Cancer: Good, Bad, or Both?
- (2013) R. Kang et al. CLINICAL CANCER RESEARCH
- Checkpoint blocking antibodies in cancer immunotherapy
- (2013) Chrisann Kyi et al. FEBS LETTERS
- [18F]-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Response Evaluation of Oncolytic Adenovirus Treatments of Patients with Advanced Cancer
- (2013) Anniina Koski et al. HUMAN GENE THERAPY
- Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy
- (2013) Christin Wittwer et al. INTERNATIONAL JOURNAL OF CANCER
- Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
- (2013) Ilkka Liikanen et al. MOLECULAR THERAPY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients
- (2013) Weiling He et al. World Journal of Surgical Oncology
- Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy
- (2012) Tao Li et al. BJU INTERNATIONAL
- Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus
- (2012) I. Diaconu et al. CANCER RESEARCH
- Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
- (2012) S. Pesonen et al. CANCER RESEARCH
- Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells
- (2012) Anna Fialová et al. INTERNATIONAL JOURNAL OF CANCER
- Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
- (2012) Yvonne Nadine Fahmueller et al. INTERNATIONAL JOURNAL OF CANCER
- CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica
- (2012) A. Uzawa et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer
- (2012) Otto Hemminki et al. MOLECULAR THERAPY
- SPECT/CT Imaging of hNIS -Expression after Intravenous Delivery of an Oncolytic Adenovirus and 131I
- (2012) Maria Rajecki et al. PLoS One
- Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy
- (2012) Oliver J. Stoetzer et al. TUMOR BIOLOGY
- In vivoandin vitrodistribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments
- (2011) Sophie Escutenaire et al. ANNALS OF MEDICINE
- Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
- (2011) Sari Pesonen et al. INTERNATIONAL JOURNAL OF CANCER
- Knockdown of HMGB1 in Tumor Cells Attenuates Their Ability To Induce Regulatory T Cells and Uncovers Naturally Acquired CD8 T Cell-Dependent Antitumor Immunity
- (2011) Z. Liu et al. JOURNAL OF IMMUNOLOGY
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
- (2011) Alan Melcher et al. MOLECULAR THERAPY
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
- (2011) Vincenzo Cerullo et al. MOLECULAR THERAPY
- HMGB1 and RAGE in Inflammation and Cancer
- (2010) Gary P. Sims et al. Annual Review of Immunology
- Oncolytic adenovirus based on serotype 3
- (2010) O Hemminki et al. CANCER GENE THERAPY
- Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
- (2010) Vincenzo Cerullo et al. CANCER RESEARCH
- Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
- (2010) P. Nokisalmi et al. CLINICAL CANCER RESEARCH
- Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
- (2010) S Pesonen et al. GENE THERAPY
- MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors
- (2010) Matthias Leisegang et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
- (2010) Anniina Koski et al. MOLECULAR THERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas
- (2010) Guoqiang Bao et al. World Journal of Surgical Oncology
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Omental Milky Spots Develop in the Absence of Lymphoid Tissue-Inducer Cells and Support B and T Cell Responses to Peritoneal Antigens
- (2009) Javier Rangel-Moreno et al. IMMUNITY
- HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
- (2009) James F Curtin et al. PLOS MEDICINE
- High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease
- (2008) T. Hoshina et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started